Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
34 Leser
Artikel bewerten:
(0)

FDA Recalls - Before You Start, and After You Finish: 2-Day In-Person Seminar by Ex-FDA Official - Research and Markets

DUBLIN, November 4, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "FDA Recalls - Before You Start, and After You Finish: 2-Day In-Person Seminar by Ex-FDA Official " conference to their offering.

FDA's recall authority and program launches you into a project of crisis management. You will learn how to establish a roadmap for conducting recalls. The knowledge you gain will sharpen your recall management decisions and strategy. You will learn how to use the FDA's health risk criteria so you can develop effective recall procedures. One critical aspect of recalls involves the identification of the root cause of the recall and how you could or should prevent that problem from happening again. Your corrective and preventive action program (CAPA) and quality assurance functions require a rigorous approach to prevent a chronic history of recalls. Reiterative recalls lead the FDA to the conclusion that, "You don't get it."

Your compliance competency becomes a regulatory issue for the FDA if your recall is deemed ineffective. The seminar will cover critical performance targets for conducting an effective recall. You will learn how missteps in the recall process become an expensive problem in terms of money and a sloppy corporate image.

You will take away practical knowledge on how to work with FDA staff during a recall, and how you can prepare for inspectional follow up or a regulatory action, and in some cases a legal action. You will learn that your approach to recalls plays a major role in mitigating direct and indirect damage to your firm's business. A firm with a history of chronic recalls needs to learn how to get out of that downward spiral. Likewise, for established and new firms you will learn how you can reduce the negative impact of a recall with the use of proper planning.

Learning Objectives:

- Understand FDA's recall authority and policy

- Learn how to manage recalls under FDA oversight

- Learn how to interact with FDA

- See how to develop health risk determinations

- Learn critical recall strategy components

- Manage possible FDA enforcement actions

Topic Background:

The products regulated by the FDA can cause serious adverse health consequences or death. The FDA's recall program is designed to make sure firms' recalls can mitigate such problems, even when the adverse consequence seems remote. The FDA's recall program has remained relatively the same over several years. How the FDA and industry manage recalls and learn from their mistakes continues to evolve. In some ways recalls have become more efficient through the benefit of technology. In other ways the reason for recalls remains substantially the same. The FDA's recall procedures and regulatory management of any risk to health are still sufficient to determine whether a recall is effective and whether manufacturers learn from their mistakes. Who Should Attend:

Who will Benefit:

- Recall managers

- Quality assurance managers

- Regulatory affairs directors

- Risk and product liability managers

- Manufacturers' sales and marketing managers

- Own label distributors

Companies and departments:

- Manufacturers

- Own Label Distributors

- Importers

- Healthcare institutions

- Nursing homes

- Medical practice groups Agenda:

Day One (8:30 AM - 4:30 PM)

8:30 AM - 9:00 AM: Registration Process

9:00 AM: Session Start

Day 1 - Morning

FDA's Regulatory Authority

Recall Regulations Voluntary recall: 21 Code of Federal Regulations (C.F.R.) Part 7 Mandatory recall actions 21 C.F.R. Part 810 21 C.F.R. Part 806 Recall Classification Violation of the law

Break (10:30 a.m. - 10:45 a.m.)

Risk to Health Precedents Exemptions Stock Recovery Product Withdrawal Product Improvement

Lunch (12:00 p.m. to 1:00 p.m.)

Day 1 / Afternoon

Recalls and risk to health

Risk to health categories Death Serious injury / serious illness Non-reversible / reversible May cause, if it were to recur Remote possibility

Break (2:30 p.m. - 2:45 p.m.)

Health Hazard Evaluation for Recall Classification FDA's internal evaluation Vulnerable subpopulations Scoring Participants Industry HHE equivalent FDA's recall database

Day Two (8:30 AM - 4.30 PM)

Day 2 / Morning

FDA's Recall Procedures

Understanding FDA's program and implementation FDA's agency-wide recall procedures The FDA's investigator's job Preparing a recall strategy

Break (10:30 a.m. - 10:45 a.m.)

Preparing for FDA oversight Recall notification to FDA's District Office Recall notification to the public

Lunch (12:00 p.m. to 1:00 p.m.)

Day 2 / Afternoon

Root cause identification

Correction and Prevent Action (CAPA)

Break (2:30 p.m. - 2:45 p.m.)

FDA inspectional follow up

Enforcement: FDA administrative and legal remedies

End

Speakers:

Casper (Cap) Uldriks

Former Associate Center Director

FDA's CDRH

Through his firm Encore Insight LLC, Casper brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. His comments are candid, straightforward and of practical value. He understands how FDA thinks, how it operates and where it is headed. Based on his exceptionally broad experience and knowledge, he can synthesize FDA's domestic and international operational programs, institutional policy and thicket of legal variables into a coherent picture.

For more information about this conference visit http://www.researchandmarkets.com/research/8cpsvx/fda_recalls

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.